Burzynski Research Institute, Inc. (BZYR) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.28: the stock has moved about 72% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBurzynski Research Institute, Inc. (BZYR) trades at $0.002. Burzynski Research Institute, Inc. focuses on researching and developing antineoplaston drugs for cancer treatment. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for BZYR: BZYR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BZYR against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BZYR: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Burzynski Research Institute, Inc. (BZYR) Healthcare & Pipeline Overview
Burzynski Research Institute, Inc., founded in 1977, is a biotechnology company focused on researching, developing, and marketing antineoplaston drugs for cancer treatment. Operating in the competitive healthcare sector, the company also provides consulting services and produces medical chemical compounds under the Antineoplastons trade name.
What Is the Investment Thesis for BZYR?
Investing in Burzynski Research Institute, Inc. (BZYR) presents a speculative opportunity due to its focus on antineoplaston drugs, a novel approach to cancer treatment. The company's potential value drivers include successful clinical trials and regulatory approvals for its Antineoplastons. However, the company's negative P/E ratio of -2.55 indicates it is not currently profitable. Key risks include the uncertainty of regulatory approval, competition from established cancer therapies, and the challenges of operating in the OTC market. The company's low beta of 0.28 suggests lower volatility compared to the broader market, but this may also reflect limited trading activity.
Based on FMP financials and quantitative analysis
BZYR Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -2.55 reflects the company's current lack of profitability.
- Beta of 0.28 suggests lower volatility compared to the overall market.
- Focus on antineoplaston drugs represents a unique approach to cancer treatment.
- The company's operations include research, development, production, marketing, and consulting services.
Who Are BZYR's Competitors?
BZYR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BETRF BetterLife Pharma Inc. | $0.23 | +4.11% | $36.5M | — |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| UCBJY UCB S.A. | $117.06 | -1.42% | $44.6B | 679-signal |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
| RPRX Royalty Pharma plc | $58.75 | -3.04% | $26.0B | 725-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BZYR's Key Strengths?
Unique antineoplaston therapies.
- Experienced leadership in cancer research.
- Established brand name (Antineoplastons).
- Dedicated focus on alternative cancer treatments.
What Are BZYR's Weaknesses?
Limited financial resources.
- Dependence on a single product line.
- Lack of profitability (negative P/E ratio).
- OTC market listing (lower liquidity and visibility).
What Could Drive BZYR Stock Higher?
Results from ongoing clinical trials of Antineoplastons for various cancer types.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Regulatory submissions for Antineoplastons in new geographic markets.
- Development of new antineoplaston formulations.
- Expansion of consulting services related to antineoplaston therapies.
What Are the Key Risks for BZYR?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established cancer therapies and larger pharmaceutical companies.
- Regulatory hurdles and uncertainty surrounding the approval of Antineoplastons.
- Adverse results from clinical trials of Antineoplastons.
- Limited financial resources and dependence on a single product line.
- OTC market listing and associated risks (low liquidity, limited disclosure).
What Are the Growth Opportunities for BZYR?
- Expansion of Clinical Trials: Burzynski Research Institute has the opportunity to expand its clinical trials to new cancer types and patient populations. Positive results from these trials could lead to increased interest in its Antineoplastons and potential regulatory approvals. The global oncology market is projected to reach $286.6 billion by 2030, providing a substantial market for successful cancer therapies. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Burzynski Research Institute with access to additional funding, expertise, and resources. Collaborations could accelerate the development and commercialization of its Antineoplastons. The pharmaceutical industry is increasingly reliant on partnerships to drive innovation. Timeline: Ongoing.
- Regulatory Approval in New Markets: Obtaining regulatory approval for its Antineoplastons in new geographic markets, such as Europe or Asia, could significantly expand the company's revenue potential. Each region has its own regulatory pathway, requiring specific clinical data and documentation. Timeline: 3-5 years.
- Development of New Antineoplaston Formulations: Developing new formulations of its Antineoplastons, such as oral or injectable versions, could improve patient convenience and compliance. This could also expand the potential applications of the drugs. The market for drug delivery technologies is growing rapidly. Timeline: 2-3 years.
- Increased Consulting Services: Expanding its consulting services related to antineoplaston therapies could generate additional revenue and strengthen the company's relationships with healthcare providers. The demand for specialized consulting services in the healthcare industry is increasing. Timeline: Ongoing.
What Are BZYR's Competitive Advantages?
- Proprietary Antineoplastons: The company's unique antineoplaston drugs represent a potential competitive advantage.
- Specialized Expertise: The company's expertise in antineoplaston therapies is a valuable asset.
- Established Brand: The Antineoplastons trade name has been in use for several years.
- Intellectual Property: Patents related to antineoplaston formulations and uses.
What Does BZYR Do?
Burzynski Research Institute, Inc., established in 1977 and based in Houston, Texas, is a biotechnology company dedicated to the research and development of antineoplaston drugs for cancer treatment. The company's core focus revolves around its proprietary Antineoplastons, which are medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids. These compounds are produced, marketed, and sold by the company. Since its inception, Burzynski Research Institute has been committed to exploring innovative approaches to cancer therapy. The company's activities encompass a range of services, including research, drug development, manufacturing, marketing, and consulting. Its primary product, Antineoplastons, represents a unique approach to cancer treatment, distinguishing it from conventional therapies. The company's operations are primarily based in the United States, with a focus on serving patients and healthcare providers seeking alternative cancer treatment options. Burzynski Research Institute also provides consulting services related to its antineoplaston therapies.
What Products and Services Does BZYR Offer?
- Researches and develops antineoplaston drugs for cancer treatment.
- Produces medical chemical compounds composed of growth-inhibiting peptides.
- Markets and promotes its Antineoplastons trade name products.
- Sells its Antineoplastons products to patients and healthcare providers.
- Offers consulting services related to antineoplaston therapies.
- Focuses on alternative cancer treatment options.
How Does BZYR Make Money?
- Generates revenue through the sale of Antineoplastons.
- Provides consulting services to healthcare providers and patients.
- Invests in research and development of new antineoplaston therapies.
- Markets and promotes its products through various channels.
What Industry Does BZYR Operate In?
Burzynski Research Institute, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant competition. The company's focus on antineoplaston drugs places it in a niche market segment within the broader cancer therapeutics landscape. Competitors include companies like BETRF (Bio-Path Holdings, Inc.), BIXT (Bioxcel Therapeutics, Inc.), BVAXF (Blue Water Vaccines Inc), CPMV (CMP Pharma, Inc.), and FAMDF (Farmaceuticos Argentinos S.A.), all of which are pursuing different approaches to cancer treatment or related therapies. The biotechnology industry is driven by innovation and is subject to stringent regulatory oversight.
Who Are BZYR's Key Customers?
- Cancer patients seeking alternative treatment options.
- Healthcare providers interested in antineoplaston therapies.
- Research institutions involved in cancer research.
- Patients who have exhausted conventional cancer treatments.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 241 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 42 |
| 2026-08-26 | 42 |
| 2026-08-29 | 42 |
| 2026-09-01 | 42 |
| 2026-09-04 | 42 |
| 2026-09-07 | 42 |
| 2026-09-10 | 42 |
What changed?
The score has stayed at 42.
Over the same 18 days the stock moved -77.8%.
Burzynski Research Institute, Inc. Financial Trajectory
Burzynski Research Institute, Inc. (BZYR) reported $0 in revenue for Q3 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $329K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, BZYR averaged $-0.00 in diluted EPS.
Company Profile
Burzynski Research Institute, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Stanislaw R. Burzynski. BZYR has traded publicly since 1997.
Key Financial Metrics
A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -160.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Burzynski Research Institute, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BZYR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Unique antineoplaston therapies.
- Experienced leadership in cancer research.
- Established brand name (Antineoplastons).
- Dedicated focus on alternative cancer treatments.
Bear Case
- Limited financial resources.
- Dependence on a single product line.
- Lack of profitability (negative P/E ratio).
- OTC market listing (lower liquidity and visibility).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2026 | $0 | -$328,862 | -$0.0025 |
| Q2 FY2026 | $0 | -$333,867 | -$0.0025 |
| Q1 FY2026 | $0 | -$331,451 | -$0.0025 |
| Q4 FY2025 | $0 | -$292,798 | -$0.0022 |
Q3 FY2026 · filed 13 Jan 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
BZYR Latest News
No recent news available for BZYR.
BZYR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BZYR.
Price Targets
Wall Street price target analysis for BZYR.
BZYR MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BZYR; grades run from A+ (80-100) to F (below 30).
Leadership: Stanislaw R. Burzynski
Founder and CEO
Stanislaw R. Burzynski is the founder and CEO of Burzynski Research Institute, Inc. He is a physician and scientist who has dedicated his career to researching and developing antineoplaston therapies for cancer. Dr. Burzynski received his medical degree from the Medical University of Lublin in Poland and later moved to the United States to continue his research. He has published numerous scientific papers on antineoplastons and their potential in cancer treatment.
Track Record: Under Dr. Burzynski's leadership, Burzynski Research Institute has developed and marketed Antineoplastons for cancer treatment. He has overseen the company's research and clinical trial programs. He has faced scrutiny and controversy regarding his methods, but has also garnered a dedicated following of patients seeking alternative cancer therapies.
BZYR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Burzynski Research Institute, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and the trading of their stock can be highly speculative. Investing in OTC Other stocks carries significant risks compared to stocks listed on major exchanges like the NYSE or NASDAQ, due to less stringent regulatory oversight and reporting requirements.
- OTC Tier: OTC Other
- Limited Disclosure: OTC Other companies often have minimal financial reporting requirements, making it difficult to assess their financial health.
- Low Liquidity: Trading volume is typically very low, leading to wide bid-ask spreads and potential price volatility.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight than exchange-listed stocks, increasing the risk of fraud or mismanagement.
- Going Concern Risk: Companies in the OTC Other tier may be facing financial difficulties or have a limited operating history.
- Information Asymmetry: Lack of readily available information can create an uneven playing field for investors.
- Verify the company's legal standing and registration.
- Review any available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products or services and their market potential.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Longevity of Operations: The company has been in operation since 1977.
- Focus on Research and Development: The company is actively involved in research and development of cancer therapies.
- Scientific Publications: The company has published scientific papers on antineoplastons.
- CEO with Medical Background: The CEO, Stanislaw R. Burzynski, is a physician and scientist.
- Dedicated Patient Following: The company has a dedicated following of patients seeking alternative cancer therapies.
What Investors Ask About Burzynski Research Institute, Inc. (BZYR) — Healthcare
Is BZYR a good stock?
Stock Expert AI does not rate BZYR buy, sell or hold. Burzynski Research Institute, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about BZYR stock?
There is currently no available analyst coverage for Burzynski Research Institute, Inc. (BZYR) due to its listing on the OTC Other market and limited financial information. The company's negative P/E ratio of -2.55 indicates it is not currently profitable.
What are the key factors to evaluate for BZYR?
Evaluate BZYR on fundamentals, analyst consensus, and risk factors. Investing in Burzynski Research Institute, Inc. (BZYR) presents a speculative opportunity due to its focus on antineoplaston drugs, a novel approach to cancer treatment. Not financial advice.
How frequently does BZYR data refresh on this page?
BZYR's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BZYR's recent stock price performance?
Burzynski Research Institute, Inc. (BZYR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Unique antineoplaston therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BZYR overvalued or undervalued right now?
Burzynski Research Institute, Inc. (BZYR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BZYR?
Yes, most major brokerages offer fractional shares of Burzynski Research Institute, Inc. (BZYR) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BZYR's earnings and financial reports?
Burzynski Research Institute, Inc. (BZYR) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BZYR earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information is available for Burzynski Research Institute, Inc. due to its OTC market listing.
- Analyst coverage is not available for the company.
- The company's future prospects are subject to regulatory approval and clinical trial outcomes.